Project dates: July 2013 - March 2019
Principal Investigator: Campbell A
On World AIDS Day, December 1, 2011, the NYC Department of Health and Mental Hygiene (NYCDOHMH) announced a new policy that all HIV positive individuals should be offered antiretroviral treatment (ART). The NYCDOHMH set a goal for this new policy: that by one year post HIV diagnosis, 80% of new HIV diagnoses will have reached viral suppression, meaning the level of virus in the blood is undetectable. The study evaluated the implementation of the policy, and examined the most efficient use of available resources for achieving this goal. Successfully implementing this policy and reaching its goal would lead to an “AIDS-free” generation in New York City.Abstract on NIH RePORTER
HIV treatment knowledge in the context of “Treatment as Prevention” (TasP)
AIDS and Behavior, 24 (10), 2984-2994. doi: 10.1007/s10461-020-02849-7. PMCID: PMC7483279.
Paschen-Wolff MM, Campbell ANC, Tross S, Choo TH, Pavlicova M, Des Jarlais D (2020).
DSM-5 substance use disorder symptom clusters and HIV antiretroviral therapy (ART) adherence
AIDS Care, 32 (5), 645-650. doi: 10.1080/09540121.2019.1686600. PMCID: PMC7103534.
Jefferson KA, Kersanske LS, Wolfe ME, Braunstein SL, Haardorfer R, Des Jarlais DC, Campbell ANC, Cooper HL (2019).
Place-based predictors of HIV viral suppression and durable suppression among heterosexuals in New York City
AIDS Care, 31 (7), 864-874. doi: 10.1080/09540121.2018.1545989. PMCID: PMC6582362.
Des Jarlais DC, McKnight C, Feelemyer J, Arasteh K, Tross S, Campbell ANC, Cooper HLF, Perlman DC (2018).
Heterosexual male and female disparities in HIV infection at the end of an epidemic: HIV infection among persons who inject drugs in New York City, 2001-2005 and 2011-2015
Drug and Alcohol Dependence, 185, 391-397. doi: 10.1016/j.drugalcdep.2017.12.039. PMCID: PMC6584620.
Campbell ANC, Wolff M, Weaver L, Des Jarlais D, Tross S (2018).
“It’s never just about the HIV:” HIV primary care providers’ perception of substance use in the era of “universal” antiretroviral medication treatment
AIDS and Behavior, 22 (3), 1006-1017. doi: 10.1007/s10461-017-2007-z. PMCID: PMC5850963.
Jefferson KA, Kersanske LS, Wolfe ME, Braunstein SL, Haardorfer R, Des Jarlais DC, Campbell ANC, Cooper HLF (2017).
Place-based predictors of HIV viral suppression and durable suppression among men who have sex with men in New York City
AIDS and Behavior, 21 (10), 2987–2999. doi: 10.1007/s10461-017-1810-x. PMCID: PMC6626637.
Campbell AN, Des Jarlais D, Hannah C, Braunstein S, Tross S, Kersanske L, Borges C, Pavlicova M, Jefferson K, Newville H, Weaver L, Wolff M (2016).
Antiretroviral medication treatment for all HIV-infected individuals: A protocol using innovative multilevel methodologies to evaluate New York City’s universal ART policy among problem substance users
BMC Health Services Research, 16, 341. doi: 10.1186/s12913-016-1554-8. PMCID: PMC4971753.
Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Campbell AN, Tross S, Smith L, Cooper HL, Hagan H, Perlman D (2016).
Consistent estimates of very low HIV incidence among people who inject drugs: New York City, 2005-2014
American Journal of Public Health, 106 (3), 503-508. doi: 10.2105/AJPH.2015.303019. PMCID: PMC4815962.
Des Jarlais DC, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper HLF, Campbell AN, Tross S, Perlman DC (2016).
Providing ART to HIV seropositive persons who use drugs: Progress in New York City, prospects for “ending the epidemic”
AIDS and Behavior, 20 (2), 353-362. doi: 10.1007/s10461-015-1028-8. PMCID: PMC4559487.